Erythropoietin in Glaucoma: From Mechanism to Therapy.
erythropoietin
glaucoma
neuroprotection
retinal ganglion cell
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
03 Feb 2023
03 Feb 2023
Historique:
received:
24
12
2022
revised:
26
01
2023
accepted:
27
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
Glaucoma can cause irreversible vision loss and is the second leading cause of blindness worldwide. The disease mechanism is complex and various factors have been implicated in its pathogenesis, including ischemia, excessive oxidative stress, neurotropic factor deprivation, and neuron excitotoxicity. Erythropoietin (EPO) is a hormone that induces erythropoiesis in response to hypoxia. However, studies have shown that EPO also has neuroprotective effects and may be useful for rescuing apoptotic retinal ganglion cells in glaucoma. This article explores the relationship between EPO and glaucoma and summarizes preclinical experiments that have used EPO to treat glaucoma, with an aim to provide a different perspective from the current view that glaucoma is incurable.
Identifiants
pubmed: 36769310
pii: ijms24032985
doi: 10.3390/ijms24032985
pmc: PMC9917746
pii:
doi:
Substances chimiques
Erythropoietin
11096-26-7
Epoetin Alfa
64FS3BFH5W
Neuroprotective Agents
0
Receptors, Erythropoietin
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Tri-Service General Hospital
ID : TSGH-E-111239
Organisme : the Ministry of National Defense-Medical Affairs Bureau
ID : MND-MAB-D-110-131
Organisme : the Ministry of National Defense-Medical Affairs Bureau
ID : MND-MAB-D-111137
Références
FEBS Lett. 2004 Dec 3;578(1-2):90-4
pubmed: 15581622
Curr Gene Ther. 2013 Aug;13(4):275-81
pubmed: 23773177
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10659-64
pubmed: 12130665
Life Sci. 2020 Feb 15;243:117303
pubmed: 31953158
J Glaucoma. 2021 Aug 1;30(8):666-671
pubmed: 33979111
J Cereb Blood Flow Metab. 2003 Mar;23(3):320-30
pubmed: 12621307
Gene Ther. 2002 Jul;9(14):915-21
pubmed: 12085239
J Neurosci. 2000 Sep 15;20(18):6962-7
pubmed: 10995840
Nippon Ganka Gakkai Zasshi. 1989 Jan;93(1):72-9
pubmed: 2750602
Brain Res. 2005 Jul 19;1050(1-2):15-26
pubmed: 15979589
Arch Ophthalmol. 1996 Mar;114(3):299-305
pubmed: 8600890
J Biol Chem. 1993 May 25;268(15):11208-16
pubmed: 7684373
Mol Ther Methods Clin Dev. 2017 Apr 19;5:130-141
pubmed: 28480312
Apoptosis. 2002 Jun;7(3):247-60
pubmed: 11997669
Prog Retin Eye Res. 2005 Sep;24(5):612-37
pubmed: 15919228
Ophthalmology. 2019 Sep;126(9):1273-1285
pubmed: 31443789
Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1212-8
pubmed: 17325165
Sci Rep. 2016 May 11;6:25792
pubmed: 27165400
Arch Ophthalmol. 2010 Jun;128(6):724-30
pubmed: 20547950
Nat Rev Drug Discov. 2019 May;18(5):358-378
pubmed: 30710128
J Biomed Biotechnol. 2012;2012:692609
pubmed: 22665989
Fundam Clin Pharmacol. 2020 Feb;34(1):131-147
pubmed: 31243792
Mol Ther. 2011 Nov;19(11):2072-83
pubmed: 21847101
Front Cell Dev Biol. 2020 Jun 16;8:452
pubmed: 32656207
Curr Opin Neurobiol. 2000 Jun;10(3):381-91
pubmed: 10851172
Invest Ophthalmol Vis Sci. 2010 Jan;51(1):35-46
pubmed: 19628748
FASEB J. 2005 Feb;19(2):249-51
pubmed: 15556972
Antioxid Redox Signal. 2003 Oct;5(5):641-6
pubmed: 14580321
Arch Ophthalmol. 1995 Feb;113(2):168-72
pubmed: 7864748
PLoS One. 2020 Apr 17;15(4):e0223208
pubmed: 32302311
Ophthalmology. 2014 Oct;121(10):2004-12
pubmed: 24869467
Cell Mol Neurobiol. 2008 Feb;28(2):317-29
pubmed: 17554621
Invest Ophthalmol Vis Sci. 2000 Mar;41(3):764-74
pubmed: 10711692
Glia. 2000 Oct;32(1):42-50
pubmed: 10975909
Prog Retin Eye Res. 2019 May;70:110-133
pubmed: 30513356
Ophthalmologe. 2010 Apr;107(4):347-53
pubmed: 19787355
PLoS One. 2013;8(1):e55291
pubmed: 23383140
Br J Pharmacol. 2005 Nov;146(6):903-12
pubmed: 16151434
J Neuroinflammation. 2016 Feb 15;13:39
pubmed: 26876380
Arch Ophthalmol. 2000 May;118(5):666-73
pubmed: 10815159
Free Radic Biol Med. 2009 Apr 15;46(8):1032-41
pubmed: 19136057
Mol Cell Biol. 2000 Apr;20(8):2687-95
pubmed: 10733571
FASEB J. 2005 Jul;19(9):1161-2
pubmed: 15870062
Gene Ther. 2003 Jun;10(11):955-63
pubmed: 12756416
Ophthalmic Res. 2011;46(2):98-102
pubmed: 21282966
Mol Biol (Mosk). 2010 Jul-Aug;44(4):656-63
pubmed: 20873225
Graefes Arch Clin Exp Ophthalmol. 2008 Feb;246(2):255-65
pubmed: 18004585
Am J Ophthalmol. 2000 Jan;129(1):102-4
pubmed: 10653426
Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):23
pubmed: 32785675
Mol Ther. 2016 Feb;24(2):230-239
pubmed: 26502777
Biomed Hub. 2018 Jul 13;3(2):1-11
pubmed: 31988957
Mol Neurodegener. 2022 Mar 21;17(1):23
pubmed: 35313950
Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2633-7
pubmed: 12147596
Exp Neurol. 2007 May;205(1):48-55
pubmed: 17328893
Gene Ther. 2010 Jan;17(1):83-94
pubmed: 19727138
Brain Res Mol Brain Res. 2000 Dec 28;85(1-2):144-50
pubmed: 11146116
Dev Neurosci. 2017;39(1-4):310-322
pubmed: 28511187
Clin Exp Ophthalmol. 2010 Aug;38(6):560-5
pubmed: 20456444
Dis Model Mech. 2018 Jun 22;11(6):
pubmed: 29752300
J Am Soc Nephrol. 2017 Aug;28(8):2377-2392
pubmed: 28302753
Mol Cell Neurosci. 2020 Dec;109:103554
pubmed: 32971229
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4580-9
pubmed: 17898281
Curr Opin Neurobiol. 2001 Jun;11(3):272-80
pubmed: 11399424
Curr Mol Med. 2013 Nov;13(9):1419-31
pubmed: 23971737
J Neurochem. 2005 Apr;93(2):392-402
pubmed: 15816862
Vis Neurosci. 1992 Jun;8(6):567-73
pubmed: 1586655
Br J Ophthalmol. 2006 Mar;90(3):262-7
pubmed: 16488940
Arch Ophthalmol. 2005 Apr;123(4):458-63
pubmed: 15824217
JAMA. 2014 May 14;311(18):1901-11
pubmed: 24825645
Exp Eye Res. 2017 Apr;157:28-33
pubmed: 28153739
Science. 2000 Oct 27;290(5492):767-73
pubmed: 11052933
Biochem Biophys Res Commun. 2006 Jun 16;344(4):1071-9
pubmed: 16643846
Hum Gene Ther. 2011 Oct;22(10):1191-200
pubmed: 21542676
Front Immunol. 2019 Apr 16;10:798
pubmed: 31040848
Invest Ophthalmol Vis Sci. 2008 Jan;49(1):342-9
pubmed: 18172111
J Cell Physiol. 1999 Aug;180(2):182-9
pubmed: 10395288
Invest Ophthalmol Vis Sci. 2004 May;45(5):1514-22
pubmed: 15111610
Front Cell Neurosci. 2018 Jul 31;12:190
pubmed: 30108483
Gene Ther. 2012 Sep;19(9):907-14
pubmed: 22052241
Arch Ophthalmol. 2003 Feb;121(2):183-8
pubmed: 12583783
J Neurosci. 2008 Mar 12;28(11):2735-44
pubmed: 18337403
Prog Retin Eye Res. 2021 Sep;84:100953
pubmed: 33640464
PLoS One. 2015 Jun 24;10(6):e0128973
pubmed: 26107378
Vision Res. 2008 Feb;48(3):353-9
pubmed: 17923143
Cell Death Dis. 2020 Feb 3;11(2):79
pubmed: 32015330
Mol Vis. 2012;18:1991-5
pubmed: 22876126
Biomed Rep. 2020 Nov;13(5):40
pubmed: 32934813
Indian J Ophthalmol. 2009 Jul-Aug;57(4):257-66
pubmed: 19574692
Curr Eye Res. 2012 Jan;37(1):1-11
pubmed: 22029631
Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2051-9
pubmed: 19933193
J Ocul Pharmacol Ther. 2008 Oct;24(5):453-9
pubmed: 18788995
Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4049-59
pubmed: 15505055
Exp Neurol. 2009 Apr;216(2):439-48
pubmed: 19320003
Graefes Arch Clin Exp Ophthalmol. 2011 Jul;249(7):1021-8
pubmed: 21360302
Neural Regen Res. 2013 Jul 5;8(19):1783-92
pubmed: 25206475
Mol Ther. 2006 Nov;14(5):710-5
pubmed: 16949343
Surv Ophthalmol. 1995 May;39 Suppl 1:S49-56
pubmed: 7660312
Brain Res. 2008 Jan 10;1188:35-43
pubmed: 18053973
Science. 1998 Sep 11;281(5383):1680-3
pubmed: 9733516
Cell Signal. 2013 Dec;25(12):2424-39
pubmed: 23958999
AMA Arch Ophthalmol. 1957 Aug;58(2):193-201
pubmed: 13443577
Cell Rep. 2019 Jun 4;27(10):2871-2880.e2
pubmed: 31167134
Invest Ophthalmol Vis Sci. 2011 Jun 23;52(7):4506-15
pubmed: 21498611
3 Biotech. 2019 Apr;9(4):131
pubmed: 30863710
J Clin Med. 2018 Feb 02;7(2):
pubmed: 29393890
Exp Neurol. 2003 Oct;183(2):610-9
pubmed: 14552902
Med Sci Monit. 2020 Apr 20;26:e920039
pubmed: 32310911
Nat Biotechnol. 2020 Feb;38(2):169-175
pubmed: 31873216
Curr Eye Res. 2005 Nov;30(11):1025-31
pubmed: 16282136
Curr Eye Res. 2018 Jun;43(6):810-820
pubmed: 29505314
J Clin Invest. 1993 Apr;91(4):1367-73
pubmed: 7682570
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3460-6
pubmed: 11006239